Bristol-Myers Squibb (NYSE:BMY) Sees Rising Interest in Sotyktu Despite 3% Share Price Dip
Bristol-Myers Squibb (NYSE:BMY) recently announced positive topline results from its Phase 3 trials for Sotyktu, generating ...
Fierce Biotech5d
Drug discovery pact between Charles River and Valo Health nets potential lupus asset for Flagship’s Pioneering Medicines
The drug discovery pact between Charles River Laboratories, Valo Health and Flagship Pioneering is starting to bear fruit. | The drug discovery pact between Charles River Laboratories, Valo Health and ...
BioSpace9d
J&J Wins Crohn’s Expansion for Tremfya as Stelara Biosimilars Enter US Market
The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar ...
Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment
Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for indolent non-Hodgkin lymphoma, which was a significant recent event. During ...
Zacks Investment Research on MSN19d
PTGX Up as J&J-Partnered Drug Meets Goal in Ulcerative Colitis Study
Protagonist Therapeutics, Inc. PTGX announced positive top-line data from the phase IIb ANTHEM-UC study, which evaluated icotrokinra (JNJ-2113), an investigational targeted oral peptide that ...
Seeking Alpha20d
Bristol Myers to acquire cell therapy partner 2seventy bio in $286M all-cash deal
2seventy bio (NASDAQ:TSVT) shares popped nearly 4% premarket on Tuesday after it entered a deal to be acquired by Bristol Myers Squibb (NYSE:BMY) in an ~$286M all-cash transaction (or $102M net of ...
Pharm Exec20d
Icotrokinra Demonstrates Promise in Moderate-to-Severe Plaque Psoriasis, Ulcerative Colitis
ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2, which are currently in progress, are comparing the safety and efficacy of icotrokinra to both placebo and Sotyktu (deucravacitinib). The dual primary endpoints ...
appliedclinicaltrialsonline20d
POETYK PsA-2 Trial Shows Efficacy of Sotyktu as an Oral Therapy for Psoriatic Arthritis
Sotyktu (deucravacitinib) demonstrated significant efficacy in improving psoriatic arthritis symptoms compared to placebo in the Phase III POETYK PsA-2 trial, with a well-tolerated safety profile.
Benzinga.com20d
Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate
The Launch-HTN trial showed lorundrostat 50 mg reduced systolic blood pressure by 16.9 mmHg, with a placebo-adjusted reduction of 9.1 mmHg. The Advance-HTN trial showed lorundrostat 50 mg achieved ...
Benzinga.com20d
Bristol Myers Unveils Positive Phase 3 Results for Sotyktu in Psoriatic Arthritis
In the POETYK PsA-2 trial, 54.2% of Sotyktu-treated patients achieved ACR20 at Week 16 vs. 39.4% on placebo. Sotyktu improved PsA disease activity, including clinical signs, extra-articular ...
FiercePharma21d
Trial results enhance Bristol Myers' bid for Sotyktu in psoriatic arthritis
Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in psoriatic arthritis (PsA), the company has presented detailed data from ...